Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BioStock via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2025-08-29 09:55:00
Lipum has published its Q2 report, which presents several important achievements in 2025. After successfully completing the phase I study, with results in line with expectations, the company is now preparing for a phase II study with SOL-116 in patients with rheumatoid arthritis. The company's CEO Ola Sandborgh comments:
– What feels best is of course the great results we got, which give us security and confidence to continue according to plan and advance SOL-116 into phase II. I think it looks promising to initiate the study in the first half of 2026.
Read the article at biostock.se:
Focus on preparation for Lipum during Q2 - Biostock